Patents Assigned to Katholieke Universiteit Leuven K.U.
-
Yeast alleles involved in maximal alcohol accumulation capacity and tolerance to high alcohol levels
Patent number: 10000759Abstract: The disclosure relates to a specific yeast allele of KIN3 that is involved in maximal alcohol accumulation and/or in tolerance to high alcohol levels. Preferably, the alcohol is ethanol. In a preferred embodiment, this specific allele is combined with specific alleles of ADE1 and/or VPS70. More specifically, the disclosure relates to the use of these alleles for the construction and/or selection of high alcohol tolerant yeasts, by stacking of positive alleles, or the selection and construction of low alcohol producing yeasts by stacking of negative alleles.Type: GrantFiled: April 15, 2014Date of Patent: June 19, 2018Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Johan Thevelein, Annelies Goovaerts, Françoise Dumortier, Maria Remedios Foulquie-Moreno, Steve Swinnen, Thiago Martins Pais -
Patent number: 9969748Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.Type: GrantFiled: June 11, 2015Date of Patent: May 15, 2018Assignees: UCB Biopharma SPRL, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Daniel James Ford, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
-
Patent number: 9957495Abstract: The disclosure provides a general method for the production of protein variants with a reduced aggregation propensity without affecting the thermodynamic stability of the variant with respect to the wild-type protein.Type: GrantFiled: April 18, 2013Date of Patent: May 1, 2018Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Frederic Rousseau, Joost Schymkowitz, Ashok Ganesan, Aleksandra Siekierska, Frederik De Smet, Joost Van Durme
-
Patent number: 9951058Abstract: The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.Type: GrantFiled: February 15, 2017Date of Patent: April 24, 2018Assignees: KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Young Sik Jung, Soo Bong Han, Chong-Kyo Lee, Hae Soo Kim, Jin Soo Shin, Johan Neyts, Hendrik Jan Thibaut, Yashwardhan Radhamohan Malpani
-
Patent number: 9908943Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: GrantFiled: September 11, 2013Date of Patent: March 6, 2018Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSELInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Publication number: 20180051345Abstract: The present application relates to the field of cancer, particular to hypoxic tumors. It was found that hypoxia is an important driver for hypermethylation of (promoters of) tumor suppressor genes. As this hypermethylation is a stable signature that is also present in circulating tumor DNA in peripheral blood, detecting this methylation pattern is a surrogate marker for tumor hypoxia. This can be used to adapt therapy as well.Type: ApplicationFiled: March 4, 2016Publication date: February 22, 2018Applicants: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, LIFE SCIENCES RESEARCH PARTNERS VZWInventors: Diether LAMBRECHTS, Bernard THIENPONT
-
Patent number: 9890133Abstract: Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.Type: GrantFiled: June 22, 2016Date of Patent: February 13, 2018Assignees: KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Young Sik Jung, Chong Kgo Lee, Hae Soo Kim, Hee Chun Jeong, Pil Ho Kim, Soo Bong Han, Jin Soo Shin, Johan Neyts, Hendrik Jan Thibaut
-
Publication number: 20180015437Abstract: A novel miniaturized and highly automated method for the controlled printing of large arrays of nano- to femtoliter droplets is presented by actively transporting mother droplets over hydrophilic-in-hydrophobic micropatches. The proposed technology consists of single plate or double-plate devices where mother droplets can be actuated and hydrophilic-in-hydrophobic micropatches on one or both plates of the device where nano- to femtoliter droplets are printed. Due to the selective wettability of the more wettable hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over these arrays. The parent droplets can be moved by different droplet actuation principles, for example, by using the principle of electrowetting-on-dielectric droplet actuation. We propose another method that uses two plates that are placed on top of each other while being separated by a spacer.Type: ApplicationFiled: July 7, 2017Publication date: January 18, 2018Applicant: Katholieke Universiteit Leuven, K.U.Leuven R&DInventors: Jeroen Lammertyn, Daan Witters
-
Patent number: 9862957Abstract: The present disclosure relates to the identification of a QTL associated with high ethanol tolerance in Saccharomyces spp. More specifically, it relates to specific alleles of MKT1 and APJ1 possibly combined with a specific allele of SWS2 that are important in obtaining a high ethanol tolerance in Saccharomyces spp. It relates further to the use of such alleles in the construction of high ethanol tolerant strains, and the use of these alleles in screening for ethanol tolerance.Type: GrantFiled: July 1, 2016Date of Patent: January 9, 2018Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&DInventors: Johan Thevelein, Maria Remedios Foulquie-Moreno, Annelies Goovaerts, Steve Swinnen
-
Patent number: 9862777Abstract: The present application relates to the field of single-domain antibodies (also called nanobodies), more particularly single-domain antibodies against SOD1 protein isoforms. It also relates to the use of these nanobodies in medicine. Accordingly, methods to treat a disease using these nanobodies are provided herein. The single-domain antibodies are particularly envisaged for treatment of ALS.Type: GrantFiled: May 28, 2014Date of Patent: January 9, 2018Assignees: VIB VZW, LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Wim Robberecht, Frederic Rousseau, Joost Schymkowitz
-
Patent number: 9850502Abstract: The disclosure relates to the use of a mutant SSK1 gene encoding a truncated ssk1 protein for the construction of a mutant yeast strain with decreased glycerol production, when compared to the wild-type strain. It relates further to the use of such strains for high-yield bioethanol production, especially in high osmotic media, or on cellulosic hydrolysates, where normal yeast strains do produce a significant amount of glycerol.Type: GrantFiled: September 23, 2013Date of Patent: December 26, 2017Assignees: VIB vzw, Katholieke Universiteit Leuven, K. U. Leuven R&DInventors: Johan Thevelein, Maria Remedios Foulquie-Moreno, Georg Hubmann
-
Publication number: 20170356013Abstract: The present invention relates to genes conferring acetic acid tolerance in yeast. More specifically, the invention relates to the use of DOT5, preferably in combination with CUP2 and/or HAA1 to obtain acid tolerance in yeast. Even more preferably, the invention relates to specific alleles of said genes, and to yeast strains comprising said specific alleles.Type: ApplicationFiled: November 24, 2015Publication date: December 14, 2017Applicants: VIB vzw, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Johan Thevelein, Jean-Paul Meijnen, Maria Remedios Foulquié Moreno
-
Patent number: 9833423Abstract: Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.Type: GrantFiled: April 14, 2016Date of Patent: December 5, 2017Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & DInventors: Young Sik Jung, Chong Kgo Lee, Ihl Young Choi, Hae Soo Kim, Phil Ho Kim, Soo Bong Han, Johan Neyts, Hendrik Jan Thibaut
-
Patent number: 9821004Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.Type: GrantFiled: August 20, 2014Date of Patent: November 21, 2017Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, UNIVERSITEIT GENTInventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh
-
Patent number: 9809808Abstract: The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: GrantFiled: August 25, 2009Date of Patent: November 7, 2017Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&DInventors: Yves Briers, Rob Lavigne, Guido Volckaert
-
Patent number: 9809830Abstract: The present invention relates to a mutant NNK1 allele, especially a mutant carrying a mutation at position of amino acid 807 of the wild type sequence. The invention relates further to the use of said mutant allele to increase the fermentation rate in yeast, preferably in Saccharomyces. The mutant allele is especially useful to increase the xylose to ethanol fermentation rate.Type: GrantFiled: December 12, 2014Date of Patent: November 7, 2017Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Johan Thevelein, Mekonnen Demeke, Maria Remedios Foulquié Moreno
-
Patent number: 9790197Abstract: The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.Type: GrantFiled: December 16, 2013Date of Patent: October 17, 2017Assignees: KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Young Sik Jung, Soo Bong Han, Chong-Kyo Lee, Hae Soo Kim, Jin Soo Shin, Johan Neyts, Hendrik Jan Thibaut, Yashwardhan Radhamohan Malpani
-
Patent number: 9783803Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.Type: GrantFiled: February 9, 2015Date of Patent: October 10, 2017Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Jean-Christophe Marine, Laura Standaert
-
Patent number: 9730944Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.Type: GrantFiled: October 16, 2015Date of Patent: August 15, 2017Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Steven De Jonghe, Ling-Jie Gao, Piet Herdewijn, Jean Herman, Miyeon Jang, Pieter Leyssen, Thierry Louat, Johan Neyts, Christophe Pannecouque, Bart Vanderhoydonck
-
Patent number: 9657315Abstract: The present invention relates to recombinant microorganisms comprising an isobutanol producing metabolic pathway and methods of using said recombinant microorganisms to produce isobutanol. In various aspects of the invention, the recombinant microorganisms may comprise one or more modifications resulting in the reduction in the expression and/or activity of an endogenous transporter protein. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: GrantFiled: December 21, 2015Date of Patent: May 23, 2017Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&DInventors: Catherine Asleson Dundon, Christopher Smith, Piruz Nahreini, Johan Thevelein, Sofie Saerens